

NOTICE OF VIOLATION

Genesys Regional Medical Center
Flint, MI 48502

License No. 21-01103-04
Docket No. 030-02003

During an NRC inspection conducted on January 5 and 6, 1994, a violation of NRC requirements was identified. In accordance with the "General Statement of Policy and Procedure for NRC Enforcement Actions," 10 CFR Part 2, Appendix C the violation is listed below:

10 CFR 35.60(b) requires that, to identify its contents, a licensee conspicuously label each syringe, or syringe radiation shield that contains a syringe with a radiopharmaceutical, and that the label show the radiopharmaceutical name or its abbreviation, the clinical procedure to be performed, or the patient's name.


Contrary to the above, on many occasions since at least April 26, 1993, the licensee did not label syringes containing radiopharmaceuticals to show the radiopharmaceutical name or its abbreviation, the clinical procedure to be performed, or the patient's name.

This is a Severity Level IV violation (Supplement VI).

Pursuant to the provisions of 10 CFR 2.201, Genesys Regional Medical Center is hereby required to submit a written statement or explanation to the U.S. Nuclear Regulatory Commission, Region III, 801 Warrenville Road, Lisle, Illinois, 60532-4351, within 30 days of the date of the letter transmitting this Notice of Violation (Notice). This reply should be clearly marked as a "Reply to a Notice of Violation" and should include for each violation: (1) the reason for the violation, or, if contested, the basis for disputing the violation, (2) the corrective steps that have been taken and the results achieved, (3) the corrective steps that will be taken to avoid further violations, and (4) the date when full compliance will be achieved. If an adequate reply is not received within the time specified in this Notice, an order or a demand for information may be issued as to why the license should not be modified, suspended, or revoked, or why such other action as may be proper should not be taken. Where good cause is shown, consideration will be given to extending the response time.

JAN 21 1994

Dated _____



John A. Grobe, Chief
Nuclear Materials Inspection
Section 2